The merger with Scipher is the dominant catalyst. Monitor for SEC review of the S-4, shareholder vote, and closing expected by year-end 2026. The standalone cash position is insufficient beyond Q1 2027, making deal completion critical. Post-merger, the key catalyst is the Phase 2 RA trial initiation in H1 2027 and data in H1 2028. The CVRs provide optionality on nebokitug milestones but are not tradeable.
Price Chart
Executive Summary
Chemomab reported Q2 2026 financial results and provided a corporate update centered on the proposed all-stock merger with Scipher Medicine. The company had $6.7M in cash as of June 30, 2026, with a net loss of $2.2M for the quarter. The merger, which values the combined company at $150M pre-money, would give Chemomab shareholders ~32% ownership and CVRs tied to nebokitug milestones, with the combined entity trading under 'SCIP'. The filing also includes a going-concern warning, noting cash runway only through Q1 2027 absent the merger closing, and the company has no approved products or revenue.
Key Facts
- Cash, cash equivalents and short-term bank deposits were $6.7M as of June 30, 2026, down from $8.0M as of March 31, 2026.
- Net loss for Q2 2026 was $2.2M, compared to $2.1M in Q2 2025.
- R&D expenses were $1.1M in Q2 2026 vs $1.3M in Q2 2025; G&A expenses were $1.1M vs $1.0M.
- Chemomab entered a definitive merger agreement with Scipher Medicine on July 7, 2026, an all-stock transaction valuing the combined company at $150M pre-money.
- Chemomab shareholders are expected to own ~32% of the combined company; Scipher holders ~68%, prior to a concurrent $30M PIPE.
- Chemomab shareholders will receive CVRs: $10M upon FDA approval of nebokitug for any indication and $40M if the PSC program advances to Phase 3 or is partnered.
- The combined company expects to trade on Nasdaq under ticker 'SCIP' and focus on a Phase 2 RA trial of nebokitug, with topline results expected H1 2028.
- The company has incurred recurring losses of ~$116M, negative operating cash flow of $3.7M in H1 2026, and no approved products, raising substantial doubt about its ability to continue as a going concern.
- Cash runway is expected to fund operations only through Q1 2027.
- The company issued 34,760 ADSs under the LifeSci ATM during H1 2026 for net proceeds of ~$68K.
Financial Impact
Cash burn of $1.3M per quarter; cash runway through Q1 2027; merger provides $30M PIPE to extend runway through Phase 2 RA readout in H1 2028
Risk Factors
- Merger may not close due to failure to obtain shareholder approval, SEC review issues, or tax rulings from the Israel Tax Authority.
- The company has a going-concern warning and only ~6 months of cash runway without the merger closing.
- Nebokitug is still in clinical development with no approved products and faces significant regulatory and clinical risk.
- The combined company's stock will trade under a new ticker (SCIP), and current CMMB holders will own only ~32% of the combined entity.
- The CVRs are non-transferable and contingent on future milestones that may never be achieved.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004193 |
| Exhibit: exhibit_99-2.htm | 0001178913-26-004193 |
| Exhibit: exhibit_99-3.htm | 0001178913-26-004193 |
| Document: zk2635899.htm | 0001178913-26-004193 |
| Document: 0001178913-26-004193-index-headers.html | 0001178913-26-004193 |
| Document: 0001178913-26-004193-index.html | 0001178913-26-004193 |
| Document: 0001178913-26-004193.txt | 0001178913-26-004193 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | 6-K | $2.09 $2.80 | ▲ +33.97% | ▲ +35.92% | $1.30 (−37.80%) |
Aug 19, 2026 6w ago | Press Release | $2.09 $2.80 | ▼ −33.97% | ▼ −35.92% | $1.30 (+37.80%) |
Jul 8, 2026 12w ago | 6-K | $1.97 $1.75 | ▼ −11.17% | ▼ −14.44% | $1.30 (−34.01%) |
Jun 2, 2026 17w ago | 6-K | $1.72 $2.27 | ▲ +31.98% | ▲ +32.98% | $1.30 (−24.42%) |
May 14, 2026 20w ago | 6-K | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 14, 2026 20w ago | Press Release | $1.70 $1.65 | ▼ −2.94% | ▼ −2.08% | $1.30 (−23.53%) |
May 6, 2026 21w ago | 6-K | $1.74 $1.72 | ▼ −1.15% | ▼ −4.29% | $1.30 (−25.29%) |
Mar 19, 2026 28w ago | Press Release | $1.93 $1.67 | ▼ −13.47% | ▼ −21.09% | $1.30 (−32.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access